These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 34357961)

  • 81. HD CAGnome: a search tool for huntingtin CAG repeat length-correlated genes.
    Galkina EI; Shin A; Coser KR; Shioda T; Kohane IS; Seong IS; Wheeler VC; Gusella JF; Macdonald ME; Lee JM
    PLoS One; 2014; 9(4):e95556. PubMed ID: 24751919
    [TBL] [Abstract][Full Text] [Related]  

  • 82. N-terminal Huntingtin Knock-In Mice: Implications of Removing the N-terminal Region of Huntingtin for Therapy.
    Liu X; Wang CE; Hong Y; Zhao T; Wang G; Gaertig MA; Sun M; Li S; Li XJ
    PLoS Genet; 2016 May; 12(5):e1006083. PubMed ID: 27203582
    [TBL] [Abstract][Full Text] [Related]  

  • 83. A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.
    Suelves N; Kirkham-McCarthy L; Lahue RS; Ginés S
    Sci Rep; 2017 Jul; 7(1):6082. PubMed ID: 28729730
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown.
    Cheng HM; Chern Y; Chen IH; Liu CR; Li SH; Chun SJ; Rigo F; Bennett CF; Deng N; Feng Y; Lin CS; Yan YT; Cohen SN; Cheng TH
    PLoS Genet; 2015 Mar; 11(3):e1005043. PubMed ID: 25760041
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies.
    Dash D; Mestre TA
    Neurotherapeutics; 2020 Oct; 17(4):1645-1659. PubMed ID: 32705582
    [TBL] [Abstract][Full Text] [Related]  

  • 86. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking.
    Orr AL; Li S; Wang CE; Li H; Wang J; Rong J; Xu X; Mastroberardino PG; Greenamyre JT; Li XJ
    J Neurosci; 2008 Mar; 28(11):2783-92. PubMed ID: 18337408
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Exploring the role of high-mobility group box 1 (HMGB1) protein in the pathogenesis of Huntington's disease.
    Angelopoulou E; Paudel YN; Piperi C
    J Mol Med (Berl); 2020 Mar; 98(3):325-334. PubMed ID: 32036391
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Mitochondria-targeted molecules MitoQ and SS31 reduce mutant huntingtin-induced mitochondrial toxicity and synaptic damage in Huntington's disease.
    Yin X; Manczak M; Reddy PH
    Hum Mol Genet; 2016 May; 25(9):1739-53. PubMed ID: 26908605
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Nmnat restores neuronal integrity by neutralizing mutant Huntingtin aggregate-induced progressive toxicity.
    Zhu Y; Li C; Tao X; Brazill JM; Park J; Diaz-Perez Z; Zhai RG
    Proc Natl Acad Sci U S A; 2019 Sep; 116(38):19165-19175. PubMed ID: 31484760
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Regulation of mitochondrial morphology and cell cycle by microRNA-214 targeting Mitofusin2.
    Bucha S; Mukhopadhyay D; Bhattacharyya NP
    Biochem Biophys Res Commun; 2015 Oct; 465(4):797-802. PubMed ID: 26307536
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
    Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
    Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.
    Cho IK; Yang B; Forest C; Qian L; Chan AWS
    PLoS One; 2019; 14(3):e0214156. PubMed ID: 30897183
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance.
    Martin DDO; Schmidt ME; Nguyen YT; Lazic N; Hayden MR
    FASEB J; 2019 Mar; 33(3):3190-3197. PubMed ID: 30423259
    [TBL] [Abstract][Full Text] [Related]  

  • 94. A CAG repeat-targeting artificial miRNA lowers the mutant huntingtin level in the YAC128 model of Huntington's disease.
    Kotowska-Zimmer A; Przybyl L; Pewinska M; Suszynska-Zajczyk J; Wronka D; Figiel M; Olejniczak M
    Mol Ther Nucleic Acids; 2022 Jun; 28():702-715. PubMed ID: 35664700
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Therapies targeting DNA and RNA in Huntington's disease.
    Wild EJ; Tabrizi SJ
    Lancet Neurol; 2017 Oct; 16(10):837-847. PubMed ID: 28920889
    [TBL] [Abstract][Full Text] [Related]  

  • 96. RNA Toxicity and Perturbation of rRNA Processing in Spinocerebellar Ataxia Type 2.
    Li PP; Moulick R; Feng H; Sun X; Arbez N; Jin J; Marque LO; Hedglen E; Chan HYE; Ross CA; Pulst SM; Margolis RL; Woodson S; Rudnicki DD
    Mov Disord; 2021 Nov; 36(11):2519-2529. PubMed ID: 34390268
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Emerging hiPSC Models for Drug Discovery in Neurodegenerative Diseases.
    Trudler D; Ghatak S; Lipton SA
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360966
    [TBL] [Abstract][Full Text] [Related]  

  • 98. FAN1 controls mismatch repair complex assembly via MLH1 retention to stabilize CAG repeat expansion in Huntington's disease.
    Goold R; Hamilton J; Menneteau T; Flower M; Bunting EL; Aldous SG; Porro A; Vicente JR; Allen ND; Wilkinson H; Bates GP; Sartori AA; Thalassinos K; Balmus G; Tabrizi SJ
    Cell Rep; 2021 Aug; 36(9):109649. PubMed ID: 34469738
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Huntington's disease: diagnosis and management.
    Stoker TB; Mason SL; Greenland JC; Holden ST; Santini H; Barker RA
    Pract Neurol; 2022 Feb; 22(1):32-41. PubMed ID: 34413240
    [TBL] [Abstract][Full Text] [Related]  

  • 100. New Avenues for the Treatment of Huntington's Disease.
    Kim A; Lalonde K; Truesdell A; Gomes Welter P; Brocardo PS; Rosenstock TR; Gil-Mohapel J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.